TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06455267

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Now Foods L-Ornithine Capsules
Description: L-ornithine is an amino acid that helps the liver clear toxic ammonia and plays an important role in liver protection and treatment of hepatic encephalopathy. Now Foods L-ornithine capsules are an ornithine supplement containing 500mg of L-ornithine per capsule. Patients in the L-ornithine supplementation group take ornithine capsules orally twice a day, three capsules each time, for 8 weeks.
Study: NCT05446337

Intervention type: OTHER
Intervention: Open-Ended Semi-Structured Interview
Description: Examine the participation and engagement in the Diabetic Foot Care and Limb Preservation Pathway design and implementation; identifying barriers and facilitators of the process

Intervention type: OTHER
Intervention: Open-Ended Semi-Structured Interview
Description: Examine the participation and engagement in the Diabetic Foot Care and Limb Preservation Pathway design and implementation; identifying barriers and facilitators of the process

Intervention type: OTHER
Intervention: Open-Ended Semi-Structured Interview
Description: Examine the participation and engagement in the Diabetic Foot Care and Limb Preservation Pathway design and implementation; identifying barriers and facilitators of the process
Study: NCT05758701

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Iodinated Contrast Agent (Omnipaque)
Description: Standard dosage of Omnipaque for CT imaging is 100 ml. Cohort will be given a reduced dosage.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Iodinated Contrast Agent (Omnipaque)
Description: Standard dosage of Omnipaque for CT imaging is 100 ml. Cohort will be given a reduced dosage.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual Energy CT
Description: Dual energy CT scanners enable monoenergetic CT image reconstruction which allows for improved iodine image contrast.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual Energy CT
Description: Dual energy CT scanners enable monoenergetic CT image reconstruction which allows for improved iodine image contrast.
Study: NCT04754945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV or PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Given IV
Study: NCT06386458

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AThrough radiofrequency transseptal puncture system
Description: Utilizing AThrough radiofrequency transseptal puncture system for left atrial access

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional mechanical transseptal puncture needle
Description: Utilizing Traditional mechanical transseptal puncture needle for left atrial access
Study: NCT05116527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marijuana, Hash, THC, or Grass
Description: Marijuana flower with a high THC content

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo THC - marijuana flower with no THC content
Study: NCT06329128

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Study Group
Description: A 15-session (5 days a week / 3 weeks) physiotherapy and rehabilitation (electrotherapy and home program) program will be applied to both groups.~Electrotherapy application; It will consist of Hotpack (15 minutes), TENS (20 minutes), Ultrasound (10 minutes) applications. For the home program, a program consisting of isometric and isotonic exercises will be given to the muscles around the knee. The home program will be followed with an exercise diary.~In the manual therapy group, in addition to the above treatment, manual therapy will be given 3 days a week. The content of the manual therapy program is as follows;~* Patellofemoral joint superior-inferior mobilization~* Medial-lateral mobilization with active knee flexion~* Tibiofemoral joint ventral (anterior-posterior) mobilization~* Tibiofemoral traction mobilization
Study: NCT04868123

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Nerve Stimulation (TENS)
Description: Transcutaneous nerve stimulation (TENS) is a simple home base treatment to manage pain. It involves electrical current applied to the skin through self-adhering electrodes, using a TENS3000 device (TENSPros.com).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Description: Mindfulness mediation is a guided mediation process to improve awareness of being present in the moment.
Study: NCT05381909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-24714
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-24714
Description: administered orally
Study: NCT06329128

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Control Group
Description: A 15-session (5 days a week / 3 weeks) physiotherapy and rehabilitation (electrotherapy and home program) program will be applied to both groups.~Electrotherapy application; It will consist of Hotpack (15 minutes), TENS (20 minutes), Ultrasound (10 minutes) applications. For the home program, a program consisting of isometric and isotonic exercises will be given to the muscles around the knee. The home program will be followed with an exercise diary.
Study: NCT05381909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-24714
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-24714
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-24714
Description: administered orally
Study: NCT06220890

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth preparation in Class IV lesions with 2mm bevel
Description: Class IV cavity with 2 mm bevel will be restored with nano-filled composite and clinical performance will be evaluated based on FDI criteria.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth preparation in Class IV lesions with 2mm stair-step chamfer
Description: Class IV cavity with 2 mm stair step chamfer will be restored with nano-filled composite and clinical performance will be evaluated based on FDI criteria.
Study: NCT05941936

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LM103
Description: Fresh tumor samples will be resected from enrolled patients. Autologous TILs will be extracted and reinfused to corresponding patients after ex vivo stimulation, activation and extensive expansion.
Study: NCT05665998

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARC-BSI Cervical system
Description: Unilateral implantation of a 64 channel - ECoG array over the sensory motor cortex combined with an implantation of 32 channel spinal cord stimulation system over the cervical region. The system decodes the motor attempts of the participant and translates those intentions into modulation of electrical stimulation.
Study: NCT05519293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H002
Description: Small molecule, Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H002
Description: Small molecule, Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H002
Description: Small molecule, Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H002
Description: Small molecule, Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H002
Description: Small molecule, Capsule
Study: NCT05381909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: administered intravenously
Study: NCT05519293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H002
Description: Small molecule, Capsule
Study: NCT06092125

Intervention type: DEVICE
Intervention: PET/MR
Description: PET/MR device is used for pre-treatment evaluation and efficacy follow-up of four types of diseases
Study: NCT06092125

Intervention type: DEVICE
Intervention: PET/MR
Description: PET/MR device is used for pre-treatment evaluation and efficacy follow-up of four types of diseases

Intervention type: DEVICE
Intervention: PET/MR
Description: PET/MR device is used for pre-treatment evaluation and efficacy follow-up of four types of diseases

Intervention type: DEVICE
Intervention: PET/MR
Description: PET/MR device is used for pre-treatment evaluation and efficacy follow-up of four types of diseases
Study: NCT05610189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tavapadon
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tavapadon
Description: Oral tablets
Study: NCT05381909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: administered intravenously
Study: NCT06494579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Lamivudine is used in the management of human immunodeficiency virus (HIV) and Hepatitis B Virus. It is being repurposed here to assess if this can improve response to cancer immunotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-L1 Blocker
Description: PD-1 or PD-L1 blocking antibodies; there are around a dozen of these FDA approved for varying indications, and whatever is administered to a patient as standard of care (FDA APPROVED) will be continued in the patients and administered in combination with lamivudine.
Study: NCT05786274

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cerebral autoregulation monitoring
Description: Perioperative characterization of cerebral autoregulation and autonomic function; characterization of adverse events after surgery
Study: NCT06312488

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Clot Pro
Description: This study enrolls patients admitted to the Adult ICU of Milan Policlinico Hospital with a diagnosis of sepsis or septic shock. A ClotPro® TPA test is performed at admission and on day 1, 2, 3, and 7. Specific markers of coagulation (PAI-1, Plasminogen, Protein C and S) and inflammation (Il-1beta, IL-6, IL-8, TNF-alpha, ADM) are tested at enrollment. Routine laboratory tests are performed daily. Hemorrhagic and thrombotic events are searched. The study ends at 28 days or upon ICU discharge.
Study: NCT05240443

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric Surgery + Medical Management of CKD.
Description: The intervention group will include medical management and bariatric surgery, which will consist of Roux-en-Y gastric bypass or sleeve gastrectomy performed according to local practice standards. Medical management for CKD will be directed by nephrologists at St. Joseph's Healthcare Hamilton. Comorbidities such as hypertension, dyslipidemia, and type 2 diabetes will be managed at the discretion of individual nephrologists. Generally, this can include anti-hypertensives (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) for systolic blood pressure control below a target of \<140/90 mmHg (\<130/80 in patients with type 2 diabetes), statins in patients with dyslipidemia to target low-density lipoprotein \<2mmol/L for the treatment of CKD.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Management for CKD
Description: Medical management for CKD will be directed by nephrologists at St. Joseph's Healthcare Hamilton. Comorbidities such as hypertension, dyslipidemia, and type 2 diabetes will be managed at the discretion of individual nephrologists. Generally, this can include anti-hypertensives (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) for systolic blood pressure control below a target of \<140/90 mmHg (\<130/80 in patients with type 2 diabetes), statins in patients with dyslipidemia to target low-density lipoprotein \<2mmol/L for the treatment of CKD.
Study: NCT04630574

Intervention type: OTHER
Intervention: Speech evaluation with the clinical evaluation of dysarthria
Description: A first speech evaluation with the clinical evaluation of dysarthria during 30 minutes is proposed to exclude very severe dysarthria.

Intervention type: OTHER
Intervention: complete assessment of the MonPaGe computerized protocol
Description: The application records directly and anonymously stores speech productions made by the patient.
Study: NCT04517279

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Invest in My Recovery Bank
Description: The intervention has not be fully developed. It will be created in partnership with individuals serving in peer provider roles.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Peer Services
Description: Usual peer services involves supporting the process of change for individuals with mental health disorder to improve their health and wellness, live a self-directed life, and strive to reach their full potential.
Study: NCT06001411

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prone Position Training
Description: All patients were admitted to our hospital at least 3 days before surgery. Patients in the intervention group (PPT group) received the prone position training daily in the hospital, three times a day, and about 1 hours every times, for at least 3 days before surgery. On the day of admission to the hospital, the patients in the PPT group were instructed to perform prone position training by nurses who were previously trained by prone position training.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: Patients in the control group (C group) received standard perioperative care without any prone position training.
Study: NCT05220735

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 long chain polyunsaturated fatty acids (n-3 LCPUFA)
Description: 3 three fish oil capsules providing 2.1 g n-3 PUFA; 1.27 g Docosahexanoic acid (DHA) and 0.86 g Eicosapentanoic acid (EPA) capsules.~The absorption study test meals will consist of white bread with butter and honey, 6mg of labeled iron as ferrous sulfate and 300 g of distilled water. The meal will be given on two days without and with ascorbic acid. The test meals without ascorbic acid will contain 6 mg 57Fe as ferrous sulfate whereas the meals containing ascorbic acid will contain 6 mg 58Fe as ferrous sulfate.
Study: NCT06016361

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VS-200Cr
Description: Topical cream with moisturizing factors.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard of care
Description: AAD recommended course of care.
Study: NCT05662111

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etidronate
Description: The dosage of etidronate is 20 mg/kg for twee weeks and ten weeks off. Etidronate is given in capsules of 200 mg. Etidronate capsules are administered orally. During the study, participants will receive etidronate in four periods of two weeks during the twelve months of follow-up.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is given in capsules and are administered orally. During the study, participants will receive placebo in four periods of two weeks during the twelve months of follow-up.
Study: NCT05278481

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reward Message with standard introduction
Description: Each text message will be sent 6 times total over two weeks. Each message type will be combined with a standard introduction.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reward Message with culturally tailored introduction
Description: Each text message will be sent 6 times total over two weeks. Each message type will be combined with an introduction culturally tailored for Hispanic/Latino participants.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Threat/Self-efficacy with standard introduction
Description: Each text message will be sent 6 times total over two weeks. Each message type will be combined with a standard introduction.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Threat/Self-efficacy with culturally tailored introduction
Description: Each text message will be sent 6 times total over two weeks. Each message type will be combined with an introduction culturally tailored for Hispanic/Latino participants.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social norms message with standard introduction
Description: Each text message will be sent 6 times total over two weeks. Each message type will be combined with a standard introduction.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social norms message with culturally tailored introduction
Description: Each text message will be sent 6 times total over two weeks. Each message type will be combined with an introduction culturally tailored for Hispanic/Latino participants.
Study: NCT05943080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI (0.25% marcaine+ 2.0 μg/mL of adrenaline + %0.9 saline)
Description: The application is made into the anatomical space between the posterior capsule and the popliteal artery before implantation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPACK(0.25% marcaine+ 2.0 μg/mL of adrenaline + %0.9 saline)
Description: It is applied to the anatomical space between the posterior capsule and the popliteal artery with the help of USG.

Intervention type: DRUG
Group type: OTHER
Intervention: ACB ( 0.25% marcaine + %0.9 saline)
Description: It is inserted into the adductor canal by simultaneous imaging of the needle, accompanied by ultrasonography, from the level just below the sartorius muscle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACB ( 0.25% marcaine + %0.9 saline)
Description: It is inserted into the adductor canal by simultaneous imaging of the needle, accompanied by ultrasonography, from the level just below the sartorius muscle.
Study: NCT05564559

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multifamily group psychoeducation
Description: The intervention involves 8 weeks of multifamily psychoeducation for families. Duration of sessions: 75 minutes on average Context: First session: psychoeducation on substance-abuse disorders; second session; effects of addiction on the family; third session; illness management; fourth session; supporting recovery; fifth session; improving stress coping skills/stress management; sixth session; developing problem-solving skills; seventh session; strengthening the family; eighth session; working with stigma Preferred approach: face-to-face, multi-family Approach: Psychoeducation
Study: NCT05646810

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine (10 mg/ml)
Description: Lidocaine (10 mg/ml) will be injected according to established protocols using ultrasound guidance and an aseptic technique by an experienced anesthesiologist.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Description: Isotonic saline will be injected according to established protocols using ultrasound guidance and an aseptic technique by an experienced anesthesiologist.
Study: NCT06202248

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: DaRT seeds
Description: Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
Study: NCT04739384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90mg
Description: Ticagrelor 90 mg followed by Ticagrelor 60 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90mg
Description: Ticagrelor 90 mg followed by Ticagrelor 60 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg
Description: Ticagrelor 60 mg followed by Ticagrelor 90 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg
Description: Ticagrelor 60 mg followed by Ticagrelor 90 mg
Study: NCT06225622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Liposome
Description: In dose escalation study, irinotecan liposome injection will be administered by an intravenous infusion at three doses of 60 mg/m2, 70 mg/m2 and 80 mg/m2, d1, 14 days per cycle. In expansion study, irinotecan liposome injection will be administered by an intravenous infusion at the dose of RP2D, d1, 14 days per cycle.~Until the disease progresses or surgery is possible.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m2, intravenously infusion, d1, 14 days per cycle, up to 12 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 2400mg/m2, intravenous infusion, d1-2, 14 days per cycle. Until the disease progresses or surgery is possible.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LV
Description: 400mg/m2, intravenous infusion, d1, 14 days per cycle. Until the disease progresses or surgery is possible.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5mg/kg, intravenous infusion, d1, 14 days per cycle. Until the disease progresses or surgery is possible.It is used to patients in dose escalation phase and with gene mutation in extension phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 500mg/m2, intravenous infusion, d1, 14 days per cycle. Until the disease progresses or surgery is possible.For wild-type patients in extended phase studies.
Study: NCT06317103

Intervention type: DEVICE
Intervention: WADYMED endo
Description: Classification of the gastro-endoscopic images as Mucosa or Submucosa by WADYMED endo (Gastric cancer image, computer aided detection/diagnosis software)

Intervention type: OTHER
Intervention: Control group (the endoscopists)
Description: Interpretation of the gastro-endoscopic images as Mucosa or Submucosa by the endoscopists
Study: NCT05084677

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Toripalimab Combined With Concurrent Platinum-based Chemoradiotherapy
Description: Toripalimab 240mg intravenously(IV) every 3 weeks (Q3W) concurrent with chemoradiotherapy; 6 cycles of Toripalimab 240mg intravenously(IV) every 3 weeks (Q3W) after chemoradiotherapy; Toripalimab 240mg intravenously(IV) every 6 weeks (Q6W) thereafter until the whole treatment period reached one year since the beginning.
Study: NCT06298344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiamine
Description: Daily Thiamine 100 mg in 28 days